Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies

Since the year of 2000, there’re 13 ADCs on the market and 9 of them were approved in the last three years. The enthusiasm of pharmaceutical and biotechnology companies for the research and development of ADC has been increasing.

Connective tissue-specific stem and progenitor cells (also known asa mesenchymal stormal/stem cells or MSCs) have been the subject of clinical testing for various conditions, but the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models.

The therapeutic antibody market has reached a fever pitch of enthusiasm, in no small part due to successes of recent drug approvals for a host of disorders such as psoriasis, multiple sclerosis, C. difficile infections, and cancer.

As the prevalence of diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that will aid in the diagnosis and management of patients. This is a complex process that poses challenges for patients, physicians, hospitals and laboratories. What is changing in today’s world is that many hospitals are being asked to take steps toward improving proactive and preventive care, improving patient outcomes while also saving on healthcare costs associated with diabetes and diabetes complications. Laboratories are invaluable partners in addressing this challenge.